Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

Research output: Contribution to journalArticlepeer-review

294 Citations (Scopus)

Abstract

Background
Clozapine is the only antipsychotic drug licensed for treatment-resistant schizophrenia but its use is often delayed. Since previous studies, national guidelines on the use of clozapine and other antipsychotics have been disseminated to clinicians.

Aims
To determine the theoretical delay to clozapine initiation and to quantify the prior use of antipsychotic polypharmacy and high-dose antipsychotic treatment.

Method
Clinico-demographic data were extracted from the treatment records of all patients commencing clozapine in our centre between 2006 and 2010.

Results
Complete records were available for 149 patients. The mean theoretical delay in initiating clozapine was 47.7 months (s.d. = 49.7). Before commencing clozapine, antipsychotic polypharmacy and high-dose treatment was evident in 36.2 and 34.2% of patients respectively. Theoretical delay was related to illness duration (β = 0.7, P<0.001) but did not differ by gender or ethnicity.

Conclusions
Substantial delays to clozapine initiation remain and antipsychotic polypharmacy and high doses are commonly used prior to clozapine, despite treatment guidelines.
Original languageEnglish
Pages (from-to)481-485
Number of pages5
JournalBritish Journal of Psychiatry
Volume201
Issue number6
Early online date6 Sept 2012
DOIs
Publication statusPublished - Dec 2012

Keywords

  • PSYCHOSIS
  • SCHIZOPHRENIA

Fingerprint

Dive into the research topics of 'Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation'. Together they form a unique fingerprint.

Cite this